A prospective, open-label study evaluating the efficacy and safety of Surufatinib (S) in combination with CAPTEM as conversion therapy in patients with unresectable pancreatic neuroendocrine tumors (pNET)

#4049

Introduction: Surgery is the primary treatment and only possible cure for pNET. Unresectable pNET necessitates conversion therapy to obtain opportunity of radical resection. Former trials have shown potential of Surufatinib (S) and CAPTEM as conversion therapy in pNET.

Aim(s): To assess the efficacy and safety of S plus CAPTEM as conversion therapy for pNET.

Materials and methods: Patients (pts) with unresectable advanced non-functional pNET who’s Ki-67 index ranged 3%-40% and with no prior systemic therapy other than SSA were enrolled. Pts received S 250mg qd, capecitabine 750mg/m2 bid d1-14, and temozolomide 200mg/m2 qd d10-14 at 21-day cycles for 4 to 6 cycles until eligibility for surgery, disease progression, or withdrawal. The primary endpoint was R0 resection rate.

Conference:

Presenting Author: Wang Z

Authors: Wang Z, Cao D, Ke N,

Keywords: pNET, Conversion therapy, Surufatinib, CAPTEM,